Objectives
The objective of the study was to determine the incidence of NEC in pediatric cancer patients receiving chemotherapy in age group 6 months to 18 years. The other objectives were to assess the clinical and microbiological profile, outcome and its predictors. We also planned to evaluate the presence of gut dysbiosis and its significance and role of fecal calprotectin as a biomarker in NEC.